Nicole Yun, MD
Hospitalist · Chicago, ILNPI 1083270649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,484 of the $3,334 with a category attached, or 74.5%. 25 manufacturers reported payments, led by AstraZeneca at 37.1% of the total. 2025 is the largest year on record at $2,325, more than ten times the $16 reported in 2019. Among hospitalist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 62 payments — averaging $53.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$300
- E.r. Squibb & Sons, L.L.C.$274
- Exelixis Inc.$210
- Jazz Pharmaceuticals Inc.$175
- Merck$160
- plus $977 from 19 others
What the payments were for
- Consulting fees$85025%
- Food & beverage$2,48475%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $1,239 |
| Sanofi | 3 | $300 |
| E.r. Squibb & Sons, L.L.C. | 6 | $274 |
| Exelixis Inc. | 2 | $210 |
| Jazz Pharmaceuticals Inc. | 3 | $175 |
| Merck | 3 | $160 |
| EMD Serono, Inc. | 1 | $143 |
| Johnson & Johnson(2 entities) | 4 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $128 |
| Array Biopharma Inc | 3 | $91 |
| Bristol Myers Squibb | 3 | $75 |
| Novartis | 2 | $62 |
| Pfizer | 2 | $56 |
| Incyte Corporation | 2 | $49 |
| Kyowa Kirin, Inc. | 1 | $28 |
| GSK | 1 | $26 |
| Fennec Pharmaceuticals, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $17 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,334 in reported general payments places this provider in the 95th percentile of 1,328 hospitalist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hospitalist in Chicago
- Salih SamoChicago$251K
- Eric GluckChicago$80K
- Alvin ThomasChicago$28K
- Tasmeen HussainChicago$18K
- Ronnie MandalChicago$10K
- Bobby DiniotisChicago$9K
- Nael GharbiChicago$8K
- Keith SummaChicago$7K
- Alicia RauhChicago$6K
- Anish MunagalaChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.